MedTrace Logo

A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers

NCT01701089 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2016-11-02

No results posted yet for this study

Summary

This open-label, multiple dose, parallel group study will assess the monoamine oxidase in the brain by in vivo positron emission tomography (PET) and safety of RO4602522 in patients with Alzheimer disease and in healthy volunteers. Patients and volunteers will receive multiple doses of RO4602522 and up to three injections of C11-L-deprenyl-D2 used in the PET.

Conditions

  • Healthy Volunteer, Alzheimer's Disease

Interventions

DRUG

11C-L-deprenyl-D2

Intravenous injection of 11C-L-deprenyl-D2 before positron emission tomography (PET); up to 3 injections in total

DRUG

RO4602522

Multiple doses of RO4602522 for 14 days

DRUG

RO4602522

Multiple doses of RO4602522 for up to 17 days

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01701089 on ClinicalTrials.gov